Literature DB >> 31991397

Incidence and prevalence of multiple sclerosis in persian gulf area: A systematic review and meta-analysis.

Masoud Etemadifar1, Yalda Nikanpour2, Amir Neshatfar3, Marjan Mansourian4, Sean Fitzgerald5.   

Abstract

BACKGROUND: There is an unapprehended diversity in the epidemiology of multiple sclerosis (MS) in different geographical regions. In this study, for the first time, we systematically review the studies estimating the incidence and/or prevalence of MS in the Persian Gulf area. The goal is to obtain the overall incidence and prevalence of MS and elucidate the reasons for the geographical variation.
METHODS: A comprehensive literature search was carried out using MEDLINE and EMBASE through articles published between January 1985 and December 2018 on MS epidemiology in Persian Gulf countries including Bahrain, Iran, Iraq, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. Search terms included 'Multiple sclerosis', 'Incidence', 'Prevalence', 'Epidemiology', 'Persian Gulf', 'Arabian Gulf' and name of each country. Only full-text articles published in English were included. All abstracts were considered and two trained reviewers evaluated the study quality using an assessment tool specifically designed for this study.
RESULTS: 39 studies met the inclusion criteria. The mean age at disease onset varied in each country and the pooled mean age of onset was 23.11. The overall pooled MS incidence was 5.03/100,000 person-years (95% CI: 0.04 - 10.02). Prevalence was 39.31/100,000 (95% CI: 29.12 - 49.50) and the result of the meta-regression method showed that prevalence increased by 2.3% per year between 1985-2018 (p = 0.04). Quality scores ranged from 4/7 to 8/8.
CONCLUSION: The prevalence and incidence of MS in the Persian Gulf region has gone through significant changes during the past decades. This study highlights the need for future studies of MS prevalence and incidence, which will further elucidate the possible etiologies leading to periodical and geographical variations in MS incidence.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epidemiology; Incidence; Multiple Sclerosis; Prevalence; Systematic Review

Mesh:

Year:  2020        PMID: 31991397     DOI: 10.1016/j.msard.2020.101959

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  5 in total

1.  Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis.

Authors:  Mehdi Rezaee; Mohammad Hossein Morowvat; Maryam Poursadeghfard; Armin Radgoudarzi; Khosro Keshavarz
Journal:  BMC Health Serv Res       Date:  2022-01-28       Impact factor: 2.655

Review 2.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

3.  Economic burden of multiple sclerosis: a cross-sectional study in Iran.

Authors:  Mehdi Rezaee; Khosro Keshavarz; Sadegh Izadi; Abdosaleh Jafari; Ramin Ravangard
Journal:  Health Econ Rev       Date:  2022-01-03

4.  Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review.

Authors:  Raed Alroughani; Jihad Inshasi; Mona Al Khawajah; Samar Farouk Ahmed; Yaser Al Malik; Jaber Alkhabouri; Ahmed Shatila; Salman Aljarallah; Edward J Cupler; Shireen Al Qureshi; Mona Thakre; Heba Elhasin; Aly Ezzat; Sherif Roushdy
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-03-09

5.  Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab.

Authors:  Matthew Craner; Yaser Al Malik; Fawzi A Babtain; Foziah Alshamrani; Mona M Alkhawajah; Nora Alfugham; Rumaiza H Al-Yafeai; Salman Aljarallah; Seraj Makkawi; Shireen Qureshi; Marina Ziehn; Hazem Wahba
Journal:  Neurol Ther       Date:  2022-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.